ADARx Pharmaceuticals, Inc. Common Stock (ADRX) - Net Assets
Based on the latest financial reports, ADARx Pharmaceuticals, Inc. Common Stock (ADRX) has net assets worth $-251.05 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($456.33 Million) and total liabilities ($707.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See ADARx Pharmaceuticals, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-251.05 Million |
| % of Total Assets | -55.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ADARx Pharmaceuticals, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how ADARx Pharmaceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore ADARx Pharmaceuticals, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Annual Net Assets for ADARx Pharmaceuticals, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of ADARx Pharmaceuticals, Inc. Common Stock from 2024 to 2025. For live market cap and overall valuation, see market cap of ADARx Pharmaceuticals, Inc. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-202.25 Million | -47.48% |
| 2024-12-31 | $-137.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ADARx Pharmaceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7308800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $18.44 Million | % |
| Total Equity | $-202.25 Million | 100.00% |
ADARx Pharmaceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of ADARx Pharmaceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Central China Land Media Co Ltd
SHE:000719
|
$1.89 Billion |
|
EMEIS SA
PA:EMEIS
|
$1.89 Billion |
|
Galapagos NV ADR
NASDAQ:GLPG
|
$1.89 Billion |
|
Zhejiang Daily Media Group Co Ltd
SHG:600633
|
$1.89 Billion |
|
Shanghai Bailian Group Co Ltd A
SHG:600827
|
$1.89 Billion |
|
Karooooo Ltd
NASDAQ:KARO
|
$1.89 Billion |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
$1.89 Billion |
|
DRDGOLD Limited
JSE:DRD
|
$1.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ADARx Pharmaceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -137,145,000 to -202,255,000, a change of -65,110,000.
- Net loss of 73,088,000 reduced equity.
- Other factors increased equity by 7,978,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-73.09 Million | -36.14% |
| Other Changes | $7.98 Million | +3.94% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares ADARx Pharmaceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-1.34 | $17.78 | x |
| 2025-12-31 | $-1.98 | $17.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ADARx Pharmaceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2119.11%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.65 Million |
| 2025 | 0.00% | -2119.11% | 0.01x | 0.00x | $-52.86 Million |
Industry Comparison
This section compares ADARx Pharmaceuticals, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $196,543,967
- Average return on equity (ROE) among peers: -37.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. Common Stock (ADRX) | $-251.05 Million | 0.00% | N/A | $1.89 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $103.64 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $159.22 Million | 44.71% | 0.38x | $282.49 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $154.57 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $836.01 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $7.69 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.41 Billion |
About ADARx Pharmaceuticals, Inc. Common Stock
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple ind… Read more